Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 February 2025 | Story Charlene Stanley | Photo Kaleidoscope Studios
Prof Hester Klopper
Prof Hester Klopper, newly appointed Vice-Chancellor and Principal of the University of the Free State.

Re-discovering Our Institutional Heart was the theme of the official opening address of the University of the Free State (UFS) presented by newly appointed UFS Vice-Chancellor and Principal, Prof Hester Klopper, as she addressed UFS staff members in the Odeion Auditorium on the Bloemfontein Campus.

Prof Klopper sketched the current global, national, and local contexts that have affected higher education in general, and the UFS in particular, giving an overview of where the institution has come from, where it currently is, and where it is going. She emphasised the need to focus on the qualities and research areas for which the university has become well known, and to stay true to the values and principles set out in its Vision 130.

“Vision 130 illuminates our way into the future – expounding how we want to establish ourselves as a top-tier university that is continually extending its influence and impact locally, regionally, and globally,” she said.

 

The institutional heart

Prof Klopper referred to the image of a heart that is reflected in the UFS marketing logo, encouraging staff to rediscover what lies at the heart of the institution, and what sets it apart.

“A university such as ours inevitably forms and moulds the lives and characters of the people associated with it; and in turn, it too is shaped and transformed by those who have graced its campuses over the decades. It too has a character. And it certainly has a heart.”

She elaborated on the metaphorical meanings locked up within the concept of a heart, touching on how it symbolised vitality, flow, and energy, interconnectedness, and a sense of belonging. She also highlighted its significance as a beacon of resilience.

“It is associated with courage and steadfastness. Over the past 120 years, the University of the Free State has prevailed despite adversity and has managed to constantly reinvent itself in order to remain relevant, without losing sight of the values in which it is anchored,” she said.

 

Priorities for tenure

One of the broad focus areas that Prof Klopper identified as a priority during her term was establishing the UFS as an innovation and entrepreneurial ecosystem. “This includes advancing transdisciplinary research, moving towards identifying two to three core research themes that address local, regional, and global challenges, and strengthening our unique offering,” she said.

Another focus area will be working towards systemic sustainability, which will include a disciplined approach towards financial management, as well as revision and optimisation of the academic model. She also indicated that internationalisation will be a core theme during her tenure, as will the establishment of the UFS as a first-choice employer and a magnet for talent. To this end, she announced the establishment of a VC Strategic Personnel Fund to grow and attract the best academic talent.

 

Innovation through connection

Prof Klopper concluded that the heartbeat of the UFS lies in innovation through connection.

For her, innovation is expressed in the university’s cutting-edge programme content, its focus on creating a culture of entrepreneurship, optimisation of the academic model, and finding new ways to diversify income streams. On the other hand, connection is reflected in heightened internationalisation, expansive collaborative networks, and a renewed focus on transdisciplinary research and real societal impact through engaged scholarship.

“My sincere wish is that each one of you will rediscover this heartbeat and that it will inspire you this year to take our great institution to even greater heights,” she said.

 

Click to view document Click here for the official opening speech.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept